A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring

Psychiatry Research
A Elif Anıl YağcıoğluM Kâzım Yazıcı

Abstract

The aim of this study was to investigate and compare the incidence of suspected or definite cases of clozapine induced myocarditis (SDM) and clinical factors which could influence its onset in two different time periods, defined by pre- and post-cardiac monitoring at an inpatient setting, during the initiation phase of clozapine treatment. Hospital records of patients started on clozapine in the inpatient unit between 2011 and 2018 were investigated. Eight in 38 patients (11.3%) were classified as SDM after the initiation of the monitoring protocol, whereas only 1 in 33 patients (1.4%) was classified as SDM, before. Monitored and non-monitored patient groups were similar with regard to demographic and clinical variables. Diagnosis of schizoaffective disorder and use of concominant lithium, valproic acid and atypical antipsychotics were higher in patients with SDM, while clozapine dose titration was similar compared to the rest of the patients. Cardiac monitoring seems to be the main factor leading to the increase in the detection of clozapine induced myocarditis (CIM). If not monitored, the outcome of CIM can be fatal without any warning signs and symptoms. Concominant use of mood stabilizers including valproic acid and lithium...Continue Reading

References

Dec 10, 1999·Lancet·J G KilianD S Celermajer
Mar 11, 2000·Lancet·S DevarajanS M Dursun
Jan 7, 2003·Archives of General Psychiatry·Herbert Y MeltzerUNKNOWN International Suicide Prevention Trial Study Group
Jan 12, 2005·Journal of Clinical Psychopharmacology·David B MerrillDonald C Goff
Jul 17, 2008·European Journal of Pharmacology·Ju-Feng WangJames P Morgan
Jan 24, 2009·Journal of Psychopharmacology·J NielsenD Taylor
Apr 7, 2010·The Journal of Clinical Psychiatry·Kathlyn J RonaldsonJohn J McNeil
Apr 29, 2011·The Australian and New Zealand Journal of Psychiatry·Kathlyn J RonaldsonJohn J McNeil
Apr 14, 2015·Acta Psychiatrica Scandinavica·K J RonaldsonJ J McNeil
Apr 14, 2015·Acta Psychiatrica Scandinavica·J de LeonP F J Schulte
Apr 14, 2015·Acta Psychiatrica Scandinavica·O Freudenreich
May 26, 2016·Current Psychiatry Reports·Martina CurtoRoss J Baldessarini
Aug 11, 2017·The Primary Care Companion to CNS Disorders·David R Goldsmith, Robert O Cotes
Mar 6, 2018·Schizophrenia Research·Kevin J LiLynn E Delisi
Mar 6, 2018·American Journal of Therapeutics·Peter ManuJimmi Nielsen
Mar 20, 2018·Schizophrenia Research·Kristen N KnophJonathan G Leung
Mar 27, 2018·International Journal of Cardiology·Brandi L BellissimaChristopher Kenedi
Mar 27, 2018·International Journal of Cardiology·Konstantinos Savvatis, Saidi A Mohiddin
Oct 17, 2018·The Primary Care Companion to CNS Disorders·O Greg DeardorffJason Cafer
Nov 24, 2018·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Domenico De BerardisMassimo Di Giannantonio

❮ Previous
Next ❯

Citations

Jul 6, 2020·European Journal of Hospital Pharmacy. Science and Practice·Nadir YalçınKutay Demirkan
Jul 4, 2021·Asian Journal of Psychiatry·Mariko TsukijiTomihisa Niitsu
Apr 15, 2020·Psychotherapy and Psychosomatics·Jose de LeonCarlos De Las Cuevas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here